Novo Nordisk AS (OCSE:NOVO B)
kr 775.8 18.5 (2.44%) Market Cap: 3.45 Til Enterprise Value: 3.43 Til PE Ratio: 36.59 PB Ratio: 28.65 GF Score: 97/100

Q2 2021 Novo Nordisk A/S Earnings Call (London-Based Investors) Transcript

Aug 06, 2021 / 11:00AM GMT
Release Date Price: kr313.45 (-2.46%)
Operator

Hello, and welcome to the Q2 2021 Novo Nordisk A/S earnings presentation. (Operator Instructions) And I will now hand the floor to Lars Fruergaard Jorgensen, CEO. Please begin your meeting.

Lars Fruergaard Jorgensen;S;President
Novo Nordisk A;CEO & Member of Management Board

/- -

Thank you very much. I'm Lars Fruergaard Jorgensen, the CEO of Novo Nordisk. I'd like to thank Citi for hosting us on this call today. With me, I have Karsten Munk Knudsen, our Chief Financial Officer; Camilla Sylvest, Head of Commercial Strategy and Corporate Affairs. We have Doug Langa on the line, and Doug is responsible for our North American operations. And we have Martin Lange, who is responsible for development.

We will do a quick run through of the slides from our earnings release call, and then we'll be ready to take your questions.

So I have to start by reminding you that we'll be making forward-looking statements today. And that such statements are, of course, subject to risks and uncertainties as the future

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot